Gene Therapy Market Outlook Indicates Rapid Adoption Across Oncology Neurology and Hepatology

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Gene Therapy Market- (By Type (Gene silencing, Cell replacement, Gene augmentation, Other therapies), By Vector (Viral vectors (Retroviral Vectors (Gamma Retroviral Vectors, Lentiviral Vectors), Adeno-Associated Viral Vectors, Other Viral Vectors), Non-Viral Vectors (Oligonucleotides, Other Non-Viral Vectors)), By Therapeutic area (Neurology, Oncology, Hepatology, Other therapeutic areas), By Delivery method (In Vivo, Ex Vivo), By Route Of Administration (Intravenous, Other routes of administration))), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

Gene Therapy Market Size is valued at USD 2.4 Bn in 2024 and is predicted to reach USD 13.6 Bn by the year 2034 at a 19.05% CAGR during the forecast period for 2025-2034

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2215

Gene therapy represents a cutting-edge medical intervention aimed at modifying or replacing genetic material within patient cells to treat or prevent disease. Its primary goal is to correct or regulate dysfunctional genes that contribute to disease onset or progression. The global gene therapy market is witnessing robust growth, propelled by ongoing advancements in biotechnology that enable the development of innovative treatments targeting a broad spectrum of genetic disorders.

Market expansion is supported by increasing research and development initiatives, favorable regulatory environments, and strengthened partnerships between pharmaceutical and biotechnology firms. North America and Europe currently dominate the market, benefiting from well-established healthcare infrastructures, active clinical research programs, and substantial investments in gene-editing technologies. As additional gene therapy candidates progress through clinical trials and obtain regulatory approvals, the market is expected to sustain its growth trajectory, offering new therapeutic options for patients with genetic conditions and driving significant advancements in the global healthcare landscape.

List of Prominent Players in the gene therapy market:
• Novartis Ag
• Biogen Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb
• Alnylam Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Amgen, Inc.
• Orchard Therapeutics Plc
• F. Hoffmann-La Roche Ag
• Jazz Pharmaceuticals Plc
• Uniqure N.V.
• Johnson & Johnson
• Bluebird Bio, Inc.
• Biomarin Pharmaceutical Inc.
• Krystal Biotech, Inc.
• Shanghai Sunway Biotech Co. Ltd.
• Sibiono Genetech Co. Ltd.
• Ferring B.V.
• Vertex Pharmaceuticals Incorporated
• Pfizer, Inc.
• Sangamo Therapeutics, Inc.
• Regenxbio
• Ultragenyx Pharmaceutical Inc.
• Meiragtx Holdings Plc
• Anges, Inc.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
Gene therapy products undergo rigorous regulatory scrutiny prior to approval, and their ability to address the root genetic causes of diseases offers therapeutic benefits that are often more durable and effective than conventional treatments. This clinical advantage has contributed to a significant increase in regulatory authorizations, exemplified by the U.S. Food and Drug Administration (FDA) approving more than ten gene therapy products between 2021 and 2023. Furthermore, a substantial pipeline of gene therapy candidates in clinical development is expected to achieve regulatory approval in the coming years. Collectively, these factors are key drivers supporting the sustained expansion of the global gene therapy market.

Challenges:
Despite its promising potential, the gene therapy market faces several constraints that may impede broader adoption. High treatment costs limit patient access, while long-term safety concerns, requirements for post-treatment monitoring, and the risk of adverse effects necessitate careful oversight. Market growth is also constrained by complex regulatory pathways, limited reimbursement mechanisms, and challenges in achieving scalable, consistent manufacturing processes. Ethical considerations and societal perceptions regarding genetic modification further influence market acceptance. Effectively addressing these issues will be essential for ensuring continued market growth and fostering broader societal trust in gene therapy.

Regional Trends:
North America maintains a leading position in the global gene therapy market, underpinned by advanced biotechnological capabilities and a supportive regulatory framework. The presence of major industry stakeholders, combined with significant research and development investments, reinforces the region's market dominance. The United States, in particular, functions as a central hub, hosting numerous clinical trials and securing multiple product approvals. Collaborative initiatives between pharmaceutical companies and academic institutions continue to accelerate innovation, ensuring that North America remains at the forefront of expanding therapeutic options for genetic disorders.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2215

Recent Developments:
• In May 2023, Novartis acquired a candidate gene therapy from Avrobio, a company experiencing financial challenges. Novartis made an unprecedented advance payment of $87.5 million for the clinical-phase asset, with no stipulations regarding future payments. The agreement encompassed AVR-RD-04, a hematopoietic stem cell gene therapy program under investigation designed to treat the uncommon genetic disorder cystinosis.
• In April 2023, Bristol-Myers Squibb expanded its global cell therapy manufacturing network. This expansion will enable in-house viral vector production via a manufacturing facility in the United States and its activities in Libertyville, Illinois. To make this happen, the business has signed an arrangement with Novartis. The facility and its operations could generate viral vectors for both of Bristol Myers Squibb's CAR T cell treatments. This advancement furthered the company's long-term goals in cell therapy.

Segmentation of Gene therapy market-
By Type
• Gene silencing
• Cell replacement
• Gene augmentation
• Other therapies
By Vector
• Viral vectors
o Retroviral Vectors
 Gamma Retroviral Vectors
 Lentiviral Vectors
o Adeno-Associated Viral Vectors
o Other Viral Vectors
• Non-Viral Vectors
o Oligonucleotides
o Other Non-Viral Vectors
By Therapeutic area
• Neurology
• Oncology
• Hepatology
• Other therapeutic areas
By Delivery method
• In Vivo
• Ex Vivo
By Route Of Administration
• Intravenous
• Other routes of administration

By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/gene-therapy-market/2215

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.